A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity
Latest Information Update: 06 Aug 2026
At a glance
- Drugs Mecasermin rinfabate (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- Sponsors Oak Hill Bio; OHB Neonatology; Premacure; Shire; Takeda
Most Recent Events
- 03 Aug 2026 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2026 Planned primary completion date changed from 23 Jan 2026 to 31 Jul 2026.
- 25 Jul 2024 This trial has been discontinued in Sweden.